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Background: From 1999 onwards, deep brain stimulation (DBS) has been proposed as an alternative to capsulotomy in refractory
cases of obsessive-compulsive disorder (OCD). Although rechargeable implantable pulse generators (rIPGs) have been used exten-
sively in DBS for movement disorders, there are no reports on rIPGs in patients with a psychiatric DBS indication, and even
possible objections to their use.
Objective: We aim to evaluate rIPGs in OCD in terms of effectiveness, applicability, safety, and need for IPG replacement.
Methods: In this prospective before-after study recruiting from 2007 until 2012, OCD patients requiring at least one IPG replace-
ment per 18 months were proposed to have a rIPG implanted at the next IPG depletion. OCD severity was the primary outcome.
Ten patients were analyzed.
Results: Psychiatric symptoms and global functioning remained stable in the two years after as compared to the two years before
rIPG implantation. Over the same period, the prescribed OCD medication doses did not increase and the DBS stimulation parame-
ters were largely unaltered. Until the end of the follow-up (mean 43=4 years; maximum seven years), the DBS-related surgery
frequency decreased and there were no rIPG replacements. During the ﬁrst few weeks after implantation, two patients obsessively
checked the rIPG, but afterwards there were no signs of compulsively checking or recharging the rIPG. Two patients experienced
rIPG overdischarges (ﬁve occurrences in total).
Conclusions: This is the ﬁrst report on rIPGs in DBS for OCD patients. The use of rIPGs in this population appears to be effective,
applicable, and safe and diminishes the need for IPG replacements.
Keywords: Deep brain stimulation, deep brain stimulation for psychiatric disorders, obsessive-compulsive disorder, rechargeable
implantable pulse generator, rechargeable stimulator
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INTRODUCTION
Obsessive-compulsive disorder (OCD) is a psychiatric disorder
with a lifetime prevalence of 2% and is mainly characterized by
intrusive thoughts or images (obsessions) and by repetitive or ritual-
istic actions (compulsions) (1). The current treatment of OCD consists
mainly of a combination of selective serotonin reuptake inhibitors
[SSRIs] and cognitive behavioral therapy. With this treatment, how-
ever, 25–40% of patients have persistent symptoms and lasting
functional impairment. Some of these patients may beneﬁt from
neurosurgical treatment such as capsulotomy (2).
From 1999 onwards, deep brain stimulation (DBS) has been pro-
posed as an alternative to capsulotomy in these refractory cases of
OCD (3,4). Clinical trials showed major enhancement of quality of life
and dramatic improvement of OCD symptoms in about half of these
highly treatment-resistant patients (5,6). In February 2009, the Unit-
ed States Food and Drug Administration (FDA) granted a humanitar-
ian device exemption for DBS in medically refractory OCD. European
CE mark approval followed later that year (7). The main targets
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currently used for DBS in OCD are the anterior limb of the internal
capsule, the ventral striatum (including the bed nucleus of the stria
terminalis [BNST]), the nucleus accumbens and the subthalamic
nucleus (8–10).
The non-rechargeable nature of implantable pulse generator (IPG)
batteries has necessitated regular revision surgery until rechargeable
IPGs (rIPGs) were introduced and FDA and CE approved, ﬁrst in spi-
nal cord stimulation (in 2004) and later in DBS in Parkinson’s disease
and essential tremor (in 2009) (11,12).
Although rIPGs in DBS for OCD patients have been used in at least
two cases (8,13), to the best of our knowledge there are no thor-
ough reports on the use of rIPGs in this highly speciﬁc population.
Prudence on using rIPGs in DBS for OCD has been called for, usually
based on one or more of the following three arguments. First, one
could fear obsessions and compulsions regarding battery recharging
and checking (8). Secondly, the use of a rIPG requires a strict
recharging schedule, which might be interrupted accidently or due
to a lack of motivation in depressed patients. Of note, acute IPG
depletion can lead to a sudden emergence of depression, anxiety,
and even suicidality (14,15). Lastly, one might argue that regular IPG
replacements necessitate a strict and scheduled follow-up, which
can be beneﬁcial in this psychiatric population, and that patients
with a rIPG could get lost to follow-up (ESSFN 2014 Meeting Presen-
tation, R. Schuurman).




In 2007, a prospective study (ClinicalTrials.gov identiﬁer
NCT02685280), approved by the Leuven University Hospitals Ethics
Committee, was initiated. DBS for OCD patients were proposed rIPG
implantation if they had a beneﬁcial effect of DBS on the psychiatric
symptoms and needed at least one IPG replacement per 18 months.
The advantages, disadvantages, risks, and practical modalities of
using rIPGs were discussed extensively at the outpatient clinic, and
patients were allowed to think about their decision for at least one
month. Our inclusion criteria for DBS treatment and surgical target
details have been described elsewhere (10).
Twelve patients were included between October 1, 2007 and
December 31, 2012, two of which were excluded from analysis due
to their simultaneous inclusion in the yet unpublished Reclaim Study
(ClinicalTrials.gov identiﬁer NCT01135745). Only one patient who
met the inclusion criteria refused participation, because she and her
relatives considered herself incapable of recharging regularly due to
unfamiliarity with modern technical devices. Psychiatric assessment,
stimulation parameters, recharging information, pharmacotherapy,
hospitalization days, and outpatient clinic visiting frequency were
collected from two years before to two years after rIPG implantation,
while the number of surgical procedures and adverse events (AEs)
were recorded from ﬁrst DBS electrode implantation until December
31, 2014. See supplementary methods for patient labeling.
rIPG Implantation
The surgical procedure consisted of removal of both (depleted)
non-rechargeable IPGs (nrIPG), tunneling of the extension wires to
one of the existing subcutaneous pockets and implantation of a sin-
gle rIPG. All IPGs were manufactured by Medtronic (Minneapolis, MN,
USA). Details can be found in the Supporting Information Table S1.
Training
The rIPG was recharged for the ﬁrst time during the hospitalization
following the implantation under the guidance of the psychiatrist or
DBS technician. During the ﬁrst weeks after rIPG implantation, outpa-
tient clinic visits were scheduled almost weekly and there was an
open-door policy to overcome potential recharging difﬁculties.
Psychiatric Scales
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) (16), Hamilton
Anxiety Rating Scale (HAM-A) (17), Hamilton Depression Rating Scale
(HAM-D) (18), Beck Depression Inventory (BDI) (19), and Global
Assessment of Functioning (GAF) (20) were recorded at least once
per six months. For statistical analysis, these values were averaged if
they were recorded more than once per six months.
Stimulation Parameters
All reported parameters are the values as programmed with the
Medtronic N’Vision physician programming device (N’Vision).
Medication
To rate OCD medication, we used four classes: SSRIs, selective nor-
adrenalin reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),
and benzodiazepines (BZDs). Per medication class, prescribed medi-
cation was expressed as daily equivalent dose (DED). Details can be
found in the supplementary methods.
Recharging Data
Recharging data (frequency, duration, and typical coupling) were
obtained from the N’Vision. These values were recorded for each
patient at least once per six months. If these parameters were
recorded more than once per six months, the recorded values were
averaged. “Typical coupling” refers to the quality of coupling
between the recharger’s antenna and the rIPG on an eight-step
scale, with a higher number indicating better positioning and faster,
more efﬁcient recharging (21).
Design
For this prospective interventional study, a quasi-experimental
before-after design was preferred above a randomized controlled tri-
al, both for ethical reasons and because blinding the patient is very
hard due to the need for recharging. The primary outcome was
deﬁned as the change in Y-BOCS after rIPG implantation.
Statistics
Applied statistics were paired t-tests with Bonferroni correction
for comparing mean psychiatric scores, stimulation parameters and
surgery frequency. Interrupted time series (ITS) analysis was per-
formed for Y-BOCS. For comparing medication equivalent doses,
outpatient clinic visiting frequency and hospitalization periods, relat-
ed samples Friedman’s 2-way ANOVA by ranks was used, with the
related samples Wilcoxon signed rank test as post-hoc analysis.
P< 0.05 was considered statistically signiﬁcant. Calculations were
performed with IBM SPSS Statistics 22.0 (Armonk, NY, USA).
RESULTS
Demographics
Patient characteristics (ﬁve male, ﬁve female) are shown in Table 1.
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Psychiatric Assessment
In the two years before and after rIPG implantation, mean Y-BOCS
was 14.3 vs. 14.3 (P5 0.99). ITS analysis showed no signiﬁcant trend
changes (1.35; P5 0.20) nor step changes (0.193; P5 0.93) at rIPG
implantation. Comparing the same periods, changes in HAM-A (10.7
vs. 11.0), HAM-D (10.2 vs. 9.7), BDI (13.5 vs. 14.8), and GAF (72.0 vs.
71.0) were not statistically signiﬁcant either (P5 0.75; 0.64; 0.40, and
0.43, respectively) (Fig. 1). Six of our patients spontaneously men-
tioned at the outpatient clinics that the rIPG had diminished the
uncertainty intrinsic to the nrIPGs and the ﬂuctuations that came
with the battery depletions and replacement procedures. All
patients declared to be happy with the rIPG.
Stimulation Parameters
The programmed amplitude was lower during the two years
before vs. the two years after rIPG implantation (7.22 vs. 7.34V on
the right [P< .01] and 6.37 vs. 6.41V on the left [P< 0.01]). Notewor-
thy, there was a signiﬁcantly lower voltage programmed on the left
as compared to the right side during the assessed four years (6.39
vs. 7.27V; P< 0.001). After excluding patient#4, who was mainly
stimulated unilaterally, the difference was smaller (7.08 vs. 7.19V;
P< 0.001). On the day of implantation, the rIPG amplitude was pro-
grammed lower than the last nrIPG programmed amplitude (mean
voltage 6.51 vs. 7.29V; P5 0.018). Average programmed stimulation
frequency and pulse width during the two years before and after
rIPG implantation were 126.0 vs. 126.3 Hz, respectively (P5 0.02)
and 291.1 vs. 291.2 msec, respectively (P5 0.82) (Fig. 2).
Medication
Except for TCAs (0.45 vs. 0.27 DEDs; P5 0.03), no signiﬁcant
changes in prescribed DEDs during the two years before vs. after
rIPG implantation were observed (SSRI: 0.85 vs. 0.56 DEDs; P5 0.30;
Table 1. Patient Characteristics.
Patient characteristics Mean Minimum Maximum
Age at rIPG implantation 44y3m 28y5m 63y7m
Y-BOCS before ﬁrst DBS electrode implantation 32.5 30 36
Time since ﬁrst nrIPG implantation at rIPG implantation 5y11m 2y5m 10y1m
Total number of used nrIPG batteries* at rIPG implantation 17.6 4 42
Longevity of all used nrIPGs before rIPG implantation 9 m 3 m 45 m
Longevity of last used nrIPG before rIPG implantation 8 m 3 m 18 m
Follow-up since rIPG implantation 4y9m 3y2m 7y2m
*nrIPGs were always implanted bilaterally and replaced bilaterally, except in patient#4, who was mostly stimulated unilaterally.
y, year(s); m, month(s).
Figure 1. Psychiatric assessment. a–e. For all assessed psychiatric scores, the thin black lines represent the individual change in mean score averaged over the two
years before (pre) and after (post) rIPG implantation. The thick colored horizontal line expresses the average over all ten patients, while the error bar indicates the
standard deviation. f. The psychiatric score averaged over all ten patients is shown per six-month periods. The left y-axis shows the values for Y-BOCS,
HAM-A, HAM-D, and BDI, while the right y-axis shows the values for GAF. Y-BOCS, Yale-Brown Obsessive Compulsive Scale; HAM-A, Hamilton Anxiety Rating Scale;
HAM-D, Hamilton Depression Rating Scale; BDI, Beck Depression Inventory; GAF, Global Assessment of Functioning.
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SNRI: 0.33 vs. 0.30 DEDs; P5 0.41; BZD: 1.18 vs. 0.79 DEDs; P5 0.58)
(Fig. 3a). Only one patient switched between two SSRI types. One
patient was not prescribed any OCD medication during the assessed
four years.
Outpatient Clinic Visits and Hospitalizations
Between six months and two years after rIPG implantation, the
mean annual combined Psychiatry and Neurosurgery consultation
frequency was lower than during the two years before rIPG implan-
tation and than during the ﬁrst six months after rIPG implantation
(5.8 vs. 10.4 visits; P< 0.01 and 5.8 vs. 8.3 visits; P5 0.047, respective-
ly) (Fig. 3b). Similarly, between six months and two years after rIPG
implantation, the mean annual combined Psychiatry and Neurosur-
gery hospitalization duration was lower than during the two years
before rIPG implantation and than during the ﬁrst six months after
rIPG implantation (0.6 vs. 2.9 days; P5 0.036 and 0.6 vs. 4.2 days;
P< 0.01, respectively) (Fig. 3b). Neurosurgical and Psychiatric hospi-
talizations were all due to DBS-related surgery and psychiatric
decompensation, respectively. During the ﬁrst six months after rIPG
implantation, 85% of the hospitalization days were due to rIPG
implantation surgery recovery. There was no signiﬁcant difference
between the mean hospitalization duration for recovery after the
last nrIPG vs. rIPG implantation (1.2 vs. 1.8 days; P5 0.08).
Surgical Procedures
Before rIPG implantation, average annual DBS-related surgery fre-
quency (excluding the initial electrode implantation) was higher
than after rIPG implantation (1.4 vs. 0.04; P< 0.001). There were on
average 1.3 IPG replacement procedures per year before rIPG
implantation, while over the full length of the follow-up period no
rIPG needed to be replaced (P< 0.01) (Fig. 4).
Recharging
Recharging parameters are indicated in Table 2.
Adverse Events
Surgical Complications
Two surgical procedures were performed after rIPG implantation.
Patient#6 needed a surgical revision one year and ﬁve months after
rIPG implantation due to an imminent rIPG skin perforation. The sur-
gical procedure consisted of creation of a new subcutaneous pocket
with a thicker layer of overlying tissue. Patient#8 needed a unilateral
electrode and extension wire revision due to breakage as discovered
through very high impedance over one electrode contact.
There were no surgical infections from the ﬁrst DBS electrode
implantation until the end of follow-up.
Recharging
For an overview of recharging associated AEs, see supplementary
Figure S1. The most common AE directly associated with recharging
was recharger belt breakage. In total, there were nine belt breakages
in six patients (i.e., one breakage per 5y3m follow-up).
Two patients and their relatives mentioned compulsions or obses-
sions with regard to recharging during the ﬁrst weeks after rIPG
Figure 2. Stimulation parameters. Mean programmed amplitude, frequency, pulse width, and contact conﬁguration are shown over a period ranging from two
years before to two years after rIPG implantation. a. Programmed amplitude on the right sided electrode (thick line) and left sided electrode (thin line) are averaged
over all ten patients. b–c. Frequency and pulse width are shown with each row representing one patient. The used color indicates the programmed frequency or
pulse width, with increasing values from green to red. White represents a value of 0 (stimulation off). d. Contact conﬁguration. Contacts are numbered from 0 (most
ventral contact) to 3 (most dorsal contact). “C” represents the IPG case. Per contact number and per day, the amount of contacts being programmed as anode
(green) or cathode (blue) is expressed as a bar chart. In bilaterally stimulated patients, there are at least two cathodes and one anode per patient. In one electrode
lead, multiple contacts can be programmed as anode or cathode.
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implantation. In these patients, we advised to recharge once daily,
regardless of the battery status, and programmed a daily alarm tone
as a reminder. This quickly solved the problem. Based on the
N’Vision read-outs and the information provided by the patient and
his relatives, this behavior never reappeared. Later, one other patient
mentioned the need to recharge to 100% loading status at each
recharging session. Over all read-outs in all patients, the lowest
recharging interval was 0.7 days.
Recharger antenna-rIPG coupling problems occurred very early
after rIPG implantation in two patients. This problem resolved sponta-
neously when the patients became acquainted with the system. Cou-
pling problems recurred later in patient#7, who had experienced a
40 kg weight loss (body mass index drop from 35 to 24 kg/m2) over
the ﬁrst six months following bariatric surgery. The skin overlying the
rIPG had become very loose, making it hard to obtain a stable position
of the recharger’s antenna in relation to the rIPG. With education, the
patient learned how to achieve good coupling in this new situation.
Before rIPG implantation, there were in total 19 complete (IPG
read-out no longer possible) nrIPG depletions in six of our patients.
These depletions were always associated with psychiatric deteriora-
tion. After rIPG implantation, two patients experienced overdi-
scharges (complete rIPG battery depletions). Patient#1 had a total of
three overdischarges: one due to not recharging the recharging
device without clear reason, one due to a broken recharger, and one
due to intentionally not recharging during a gastro-enteritis, from
fear of worsening the stomachache. All were associated with sudden
OCD symptomworsening, for which the patient requested an urgent
appointment at the Psychiatry department, where the overdi-
scharges were detected and easily resolved by a regular recharging
session. Patient#10 had two overdischarges, both due to not
recharging during episodes of severe psychiatric worsening, the sec-
ond time even during hospitalization at an external psychiatric hospi-
tal. The ﬁrst time, the rIPG could be recharged after performing a
physician charging session, which is a charging session performed
by the physician, imperative when the battery had been depleted
long-lasting (21). After the second overdischarge, we proposed to
attempt a second physician charging session, if this would turn out
to be impossible, we would propose the patient to replace the rIPG
by a nrIPG or to perform a capsulotomy.
None of our patients mentioned a heating sensation or local skin
irritation during recharging, although patient#3 reported a strange
indescribable abdominal feeling while recharging. This feeling was
only present for ﬁve weeks, after which recharged trouble-free again.
Other
Other AEs mentioned by the patients during consultations and
hospitalizations at all departments in our hospital are summarized in
supplementary Table S2. Interestingly, while half of the patients
complained of memory defects, objective memory deﬁcits could
never be detected during neuropsychological testing.
DISCUSSION
Efﬁcacy
We found no evidence for changes in efﬁcacy of DBS for OCD
after switching to a rIPG. No signiﬁcant changes were noted for all
Figure 3. Prescribed OCD medication and Neurosurgery and Psychiatry out-
patient clinic visits and hospitalization days. a. From two years before to two
years after rIPG implantation, prescribed OCD medication DEDs per medication
class, averaged over all ten patients, are expressed as mean6 standard devia-
tion. b. From two years before to two years after rIPG implantation, the number
of outpatient clinic visits (green), and the number of hospitalization days at the
Neurosurgery (blue) and Psychiatry (red) ward are displayed. * represents
P< 0.05. SSRIs, selective serotonine reuptake inhibitors; SNRI, selective nor-
adrenalin reuptake inhibitors; TCA, tricyclic antidepressants; and BZD,
benzodiazepines.
Table 2. Recharging Parameters.
Time from rIPG implantation 0–6 m 7–12 m 13–18 m 19–24 m
Mean recharging frequency 1 3 /2.2 d 1 3 /1.4 d 1 3 /1.5 d 1 3 /1.3 d
Mean reacharging duration (h) 1.8 1.7 1.3 1.4
Mean typical coupling (/8) 7.1 7.8 7.9 8.0
rIPG, rechargeable pulse generator; m, month(s); h, hour(s); d, day(s).
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assessed psychiatric scores including Y-BOCS and no Y-BOCS step or
trend changes were observed at rIPG implantation on ITS analysis.
Although the need for regular recharging demands attention, the
global assessment of social, occupational, and psychological func-
tioning (GAF score) remained stable as well.
To prevent possible overstimulation by the new device and since
the amplitude is usually programmed higher in nearly depleted IPGs
to compensate for the decreasing battery voltage, the mean rIPG
amplitude was programmed lower immediately after implantation as
compared to the last programmed amplitude of the nrIPG (6.51 vs.
7.29V). Afterwards, the programmed amplitude was gradually
increased, reaching on average 6.70V and 6.93V one and two months
later, respectively (Fig. 2). Programmed voltage ﬂuctuated over the
assessed period. Although statistically signiﬁcant, these small
changes (<0.25V or <3.5% difference between the mean annual
amplitudes) are probably not clinically relevant. For the programmed
stimulation frequency, the same conclusion can be drawn, with the
minimal change in stimulation frequency (0.3 Hz) not even being
programmable in an individual patient. A similar initial reduction in
programmed stimulation parameters followed by a gradual increase
to a level comparable to that of a few months before rIPG implanta-
tion was observed in a study in mainly motor disorder patients (22).
Both before and after rIPG implantation, the most frequently pro-
grammed contact conﬁguration was bipolar, with contact 0 as anode
and contact 1 as cathode. This is a direct consequence of the applied
electrode implantation technique and target deﬁnition, aiming to
position contact 0 in the BNST (10). Importantly, there were no
apparent changes in contact conﬁguration after rIPG implantation.
Likewise, none of the prescribed psychiatric medication doses
were increased, and average prescribed TCA DED was even
decreased, indicating that the stable psychiatric scores were not
obtained by increased medication intake.
Both the combined Neurosurgery and Psychiatry outpatient clinic
visiting frequency and hospitalization time was lower between six
months and two years after rIPG implantation as compared to before
rIPG implantation, preceded by an initial increase during the ﬁrst six
months after rIPG implantation. For outpatient clinic visits, this
increase is at least partly due to the fact that these patients were invit-
ed to the outpatient clinic very frequently in the ﬁrst month after rIPG
implantation, for timely detection of possible recharging problems.
For rIPG implantation, our patients were hospitalized during 1.8 days
on average. This hospitalization duration does not differ from that for
implantation of the last pair of nrIPGs, but due to the applied process-
ing method these hospitalization days are now clustered together in
the same time frame, creating an apparent increase in the hospitaliza-
tion duration in the ﬁrst six months after rIPG implantation.
Note that hospitalizations at external hospitals could not be
assessed reliably and were therefore not taken into account.
Applicability
Although patient satisfaction with rIPGs in DBS for movement dis-
orders is generally high (22,23), it has been questioned whether
rIPGs are applicable in an OCD population (8). Generally, there have
been three possible objections put forward, which we can refute to
a large extent.
Compulsively and Obsessively Recharging
One could fear that OCD patients with a rIPG could become
obsessed with recharging and checking the battery status and/or
could compulsively do so (8). The mean recharging interval in our
patients is lower than the interval reported in patients with electrical
stimulation for movement disorders and pain (12), presumably with
different battery consumption compared to our series. The reported
mean recharging duration after six months (108 min/session) how-
ever, is very comparable to our series (12).
Over time there seems to be a slow decrease in recharging inter-
val and duration. However, apart from the ﬁrst few weeks after rIPG
implantation, no patient reported recharging obsessions or compul-
sions, nor was this observed in N’Vision read-outs. As the Y-BOCS
remained stable after rIPG implantation, there is no indication that
the need for recharging itself might lead to an increase in obsessive
or compulsive symptoms.
Recharging Difﬁculties With Possible Overdischarging
Acute cessation of DBS for OCD, e.g., in case of IPG depletion, can
potentially lead to the emergence of depression, anxiety, and suici-
dality (15). There is a case report of a patient experiencing a rIPG
overdischarge with a full rebound of severe OCD, depression and
suicidality within 24 hours (13). Moreover, it is considered uncertain
whether OCD patients with a depressive mood are capable of
recharging the rIPG punctually.
In our series, all patients were capable of learning how to recharge
correctly, with excellent typical coupling from the beginning (7.1/
8 during the ﬁrst six months) raising to perfect (mean 7.9/8 and 8/8)
coupling after one year. Nevertheless, two patients had ﬁve battery
overdischarges in total. However, one should keep in mind that also
in current nrIPGs, predicting the moment of battery depletion is very
difﬁcult (24). In our series, the incidence of rIPG overdischarging was
even lower than that of complete nrIPG depletion (5 per 17287
follow-up days, i.e., once per nine follow-up years vs. 19 per 21559
follow-up days, i.e., once per three follow-up years; P5 0.019).
Loss to Follow-Up
Some authors state that the need of nrIPG replacement obliges
the patient to regularly attend follow-up consultations, which might
be beneﬁcial for these patients, and that this need could be
decreased in patients having rIPGs. Although a signiﬁcant decrease
in outpatient clinic contacts is observed from six months following
Figure 4. OCD-related surgery timeline. All DBS for OCD-related operations were listed and expressed in a timeline. Each horizontal bar represents one patient (#1
on bottom row, #10 on top row). The length of the bar shows the period from ﬁrst implantation of the electrodes (marked “x”) until last follow-up. IPG replacement
for (impending) battery depletion is marked “”, extension wire revision is marked “,” revision of the abdominal pocket to create a thicker overlying tissue layer is
marked “|” and revision of one of the electrodes is marked “.” The implantation of the rIPG is marked “.”
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rIPG implantation onwards, no patients were lost to follow-up. On
the contrary, this effect can be considered as an advantage in terms
of self-conﬁdence and control, as mentioned by most of our
patients. O’Rawe also states that the rechargeable nature of the rIPG
has been reassuring for their patient, as he was able to exert control
over his battery life (13).
Safety
Both surgical complications, being an imminent skin perforation
and a broken electrode, required surgical re-intervention. We consid-
er none of the AEs, except for recharger belt breakage, as being typi-
cally associated with rIPGs.
In the literature, two surgical complications associated speciﬁcally
with the use of rIPGs have been described. First, in a patient with
DBS for Parkinson’s disease, recharging difﬁculties were noticed after
the rIPG had ﬂipped upside down, necessitating surgical reorienta-
tion, and ﬁxation (25). Secondly, two cases of the so-called “shielded
battery syndrome” have been published, in which the additional
pocket adaptor needed for replacing certain types of nrIPGs to rIPGs
migrated superﬁcially, becoming an impediment to battery recharg-
ing (26). In our series, we did not experience any of these, nor the
so-called twiddler’s syndrome, in which the patient repeatedly gives
his IPG a twiddle, ﬁnally leading to extension wire breakage (27). We
strongly believe that the risk of these three AEs can be largely
reduced by ﬁxating the rIPG in its subcutaneous pocket.
In two patients, the rIPG became overdischarged ﬁve times in
total, with severe worsening of the OCD symptoms but no
suicidality.
Reduction of IPG Replacement Frequency
In this series of patients with a high frequency of IPG replacement
procedures, rIPG usage signiﬁcantly decreased the frequency of
DBS-related surgical procedures in general and of IPG replacement
procedures in particular. The rIPGs used have a maximal longevity of
nine years (28). In our series, with three patients having a follow-up
of more than six years, no IPG needed replacement yet. The future
need for rIPG replacement procedures will probably diminish but
highly likely not completely take away this surgery frequency
reduction.
Besides bringing costs and patient discomfort, IPG replacement
inevitably holds an infection risk, which may be higher than during
initial hardware implantation. In two retrospective studies the infec-
tion rate after IPG replacements was two to three times higher than
after the initial DBS procedure (10% vs. 3.1% and 8.7% vs. 3.7%,
respectively) (29,30). Therefore, it seems reasonable that diminishing
the frequency of DBS-related surgical procedures, by using rIPGs,
decreases the risk of infection. No infections occurred in our series,
neither before nor after rIPG implantation.
Limitations
The major limitations of this study are 1) the relatively small sam-
ple size; 2) the lack of a cost analysis; 3) the lack of quality-of-life
measurements; and 4) that no qualitative question addressing the
IPG type preference was asked.
Although we report on only ten patients, this sample size can be
rated as considerable given the highly speciﬁc population and strin-
gent inclusion criteria.
A cost analysis would have been more convincing for health deci-
sion makers than our descriptive report. However, there are three
reasons why a cost analysis was not performed. First, the sample
size is too small to render reliable result in terms of costs per DALY
or QALY when comparing nrIPGs to rIPGs (31,32).
Secondly, as this is a single-center study originating from Belgium,
with a very speciﬁc health system (entirely publically funded health
system, free choice of health providers, total reimbursement for
both the IPGs and the implantation surgery, DBS for OCD surgery
limited to certain hospitals), any cost analysis resulting from this
study would represent the very local Belgian situation (31,32). Lastly,
we did not obtain informed consent to collect data such as hospitali-
zation and outpatient clinic visiting frequency in external hospitals
or with general practitioners.
We did not include a quality-of-life measurement (e.g., EQ-5D6
(33) or CDC HRQOL-4 (34)), mainly because GAF, HAM-D, and BDI
are largely overlapping with these.
A qualitative question on which system (nrIPG or rIPG) the
patients preferred would have been valuable, although also very
susceptible to recall bias.
CONCLUSIONS
Based on our series of ten patients, the use of rIPGs in this highly
speciﬁc psychiatric population appears to be effective, applicable,
safe, and capable of reducing the IPG replacement frequency. There-
fore, approval and reimbursement of the use of rIPGs for DBS in
OCD seems justiﬁed. Continued research, based on larger patient
samples with longer follow-up is needed to reﬁne which and how
DBS for OCD patients can beneﬁt maximally from rIPGs.
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